TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment
Status:
Terminated
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether TAB08 may be beneficial compared to placebo in
patients with active Systemic Lupus Erythematosus, not adequately controlled with current
concomitant treatment. Secondary purpose is to assess efficacy, safety, pharmacokinetic and
pharmacodynamic parameters in this study population.